Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNP-106 in Generalized Myasthenia Gravis
NCT06106672Phase 2Active, not recruiting
- Sponsor
- COUR Pharmaceuticals
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CNP-106 in myasthenia gravis (MG), sponsored by COUR Pharmaceuticals. Started May 2024; status: active, not recruiting.
02
Drugs
CNP-106
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06106672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106672.